BIOCYTOGEN
6.5.2024 16:01:35 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.
The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.
“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”
BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.
About Biocytogen’s TCR-mimic Antibody Discovery Platform
Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using a high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
About BioCopy
BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform, BioCopy is working continuously to develop next-generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.
Website: www.biocopy.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240506586492/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ and The OpenAI Deployment Company Collaborate to Bring Consumer Intelligence into Enterprise Workflows25.8.2026 12:45:00 CEST | Press release
Collaboration advances NIQ’s existing AI-native product strategy, enabling clients to activate NIQ intelligence through purpose-built AI applications and their own AI environments NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced a collaboration with The OpenAI Deployment Company (“DeployCo”) to further extend its AI suite of products in the NIQ Optiq Suite, including NIQ Optiq Chat, Optiq Mobile, and Optiq Bridge. The collaboration builds on the AI-native growth and product momentum NIQ reported in its Q2 results and will help NIQ extend and deliver its proprietary intelligence directly into the enterprise systems and workflows clients use every day. AI is rearchitecting decision-making across commerce, reshaping how companies analyze markets, make decisions and execute work. But model capabilities alone are not enough. Business outcomes depend on the quality of the data, harmonization, semantic context and domain intelligence behind those systems. Throug
SCP Standard Capital Partners AG Completes Its Strategic Shift Towards Defence Technology Through the Acquisition of Vanea Technologies GmbH and Nocturne Technologies GmbH – Plans to Change Its Name to VANEA AG25.8.2026 12:26:00 CEST | Press release
SCP Standard Capital Partners AG (“SCP” or the “Company”) has today agreed to acquire all shares in Vanea Technologies GmbH (“VANEA”) and Nocturne Technologies GmbH (“Nocturne”). The shares will be acquired by way of capital increases in kind, utilising the Authorised Capital 2026, in return for the issue of new shares and cash compensation. VANEA is a young technology company specialising in the development of defence solutions for the dawning era of autonomous warfare. Nocturne, based in Osnabrück – also known as Nocturne Defence – specialises in forward-looking solutions in the field of civil and military counter-UAS systems (drone defence). The purchase price for the acquisition of VANEA is in the low six-figure range and comprises a cash component and a share component. The purchase price for the acquisition of Nocturne comprises a cash component and a share component, which together amount to a figure in the high six-figure range. Going forward, the Company will focus on developi
INSEAD Marks the First Milestone in Its Europe Campus Re-imagination25.8.2026 12:07:00 CEST | Press release
INSEAD, The Business School for the World, yesterday inaugurated the Tour Desmarais, marking a major milestone in its Europe Campus Re-imagination (ECR)—a ten-year, €350 million investment totransform its campus in Fontainebleau for the future of business education and learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825752920/en/ From left: Charles Desmarais, Maria Desmarais, Nicolas Desmarais, Paul Desmarais MBA'79, Helene Desmarais, Jean-Michel Wilmotte, Francisco Veloso, Paul Desmarais III MBA'10J, Borina Andrieu The inauguration took place in the presence of members of the Desmarais family, public officials, members of the INSEAD community, partners and distinguished guests from across the business, academic and philanthropic communities. Nestled within one of Europe's most iconic forests, the INSEAD Europe Campus has welcomed students, executives, researchers and entrepreneurs from around the world for more
CTC Global Expands Advanced Conductor Portfolio with ACCC® Plus Conductor25.8.2026 12:00:00 CEST | Press release
CTC Global, the world’s leading developer and manufacturer of high-capacity Advanced Conductors, today announced the introduction of the ACCC® Plus Conductor, an enhanced addition to the ACCC® Conductor family. Utilities are facing a new set of transmission planning challenges, as load growth, generation shifts, interconnection queues, permitting constraints, and evolving reliability requirements put increasing pressure on both existing and new transmission infrastructure. Utilities must quickly add capacity while managing project costs, clearance constraints, structure requirements, and long-term performance. Built on highly proven ACCC® Conductor Technology, the ACCC® Plus Conductor is designed to deliver greater mechanical performance, improved efficiency, and enhanced sag performance, while offering greater design flexibility for demanding transmission line applications. The new conductor option features a higher-strength, higher-modulus core than standard ACCC® Conductor, supporti
From Factory to Field: emnify Launches OEM Program with Free SGP.32 Bootstrap Connectivity25.8.2026 10:00:00 CEST | Press release
emnify, a global provider of cloud-native IoT connectivity, today announced a new program for original equipment manufacturers (OEMs) building connected products for international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825932817/en/ From Factory to Field with SGP.32 Bootstrap Connectivity The program addresses two common challenges for OEMs: testing and configuring devices that would otherwise leave the factory without connectivity and managing customer-specific physical SIMs throughout production and fulfilment. It enables OEMs to ship a single device SKU globally with built-in SGP.32 bootstrap connectivity, allowing each device to connect to the relevant device-management system for connectivity testing, configuration, and digital eSIM profile provisioning - from the factory onward. Free emnify SGP.32 bootstrap profiles are available for every connected device across an OEM’s production volumes - not on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom